Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification(TM)
MWN-AI** Summary
Elutia Inc. (Nasdaq: ELUT), an innovative leader in drug-eluting biomatrix technologies based in Gaithersburg, Maryland, has proudly announced its certification as a 2026 Great Place to Work® by the renowned organization dedicated to evaluating workplace culture. This achievement reflects Elutia’s commitment to fostering a high-trust environment that encourages sustained employee engagement and retention, essential in its regulated, innovation-driven industry.
Dana Yoo, VP of Product Development at Elutia, emphasizes the company’s high standards and the significance of their work, noting that their technology profoundly impacts patients’ futures. Elutia, founded a decade ago, boasts a diverse workforce where women represent 54% of employees and 62% in leadership roles—a testament to its inclusive culture. With a median employee tenure of 6.3 years, Elutia showcases not only stability but also a mission-driven team, as half of its workforce holds advanced degrees.
Senior Director Fletcher Brehler highlights the disciplined and focused approach of the team, stating that their ability to debate and align efficiently sets them apart in the competitive landscape. Dr. Michelle Williams, co-founder and Chief Scientific Officer, underscores the dedication to uncompromising standards in developing first-in-class products, asserting that Elutia is the ideal environment for individuals driven to make a meaningful difference.
The Great Place to Work Certification is regarded globally as a hallmark of excellent workplace experience, based on employee feedback and culture assessment. Through this distinction, Elutia not only solidifies its standing as an employer of choice but also continues its mission of humanizing medicine for patients. Interested individuals are encouraged to explore career opportunities at Elutia to join its dedicated team. More information can be found at www.Elutia.com.
MWN-AI** Analysis
The recent announcement of Elutia Inc. (Nasdaq: ELUT) achieving the 2026 Great Place to Work Certification™ signals a pivotal moment not just for the company, but also presents a strategic opportunity for investors. This recognition is indicative of a high-trust workplace culture that fosters employee engagement and retention, crucial elements for innovation-driven firms operating in the regulated medical technology sector.
Elutia is distinguishing itself in a competitive market by investing in a team that values excellence and longevity, demonstrated by a median employee tenure of 6.3 years and a workforce where 54% are women. These factors contribute to creating a stable environment that encourages innovation and operational efficiency, which is likely to translate into improved financial performance. As the company develops advanced drug-eluting biomatrix products, its mission of enhancing patient outcomes is well-aligned with rising healthcare demands—especially in implantable technologies as the population ages.
From an investment perspective, Elutia’s commitment to a high-performance culture typically correlates with reduced turnover rates and superior performance against industry benchmarks, fostering a robust environment for sustained growth. The leadership team's deep-rooted expertise, particularly in regulatory execution and product development, further positions Elutia as a potential leader in its field.
Investors should consider taking positions in Elutia as it expands its product offerings and customer base. The successful acquisition of its EluPro™ product by Boston Scientific for $88 million underscores the value of its innovation and market appeal. As Elutia continues to build its reputation and enhance its product portfolio, stakeholders can anticipate future growth potential that aligns with long-term investment strategies focused on innovation and healthcare improvements. Overall, Elutia exemplifies an attractive investment opportunity buoyed by a commitment to culture, employee engagement, and groundbreaking medical technology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries.
“Elutia isn’t for everyone,” said Dana Yoo, PhD, VP of Product Development. “The bar is high, and the work is hard. But the first time I saw our technology used in surgery, I understood why. This wasn’t an experiment. It was someone’s future. It’s demanding, but if you want your work to matter, there’s no place better.” Dr. Yoo has been with Elutia for six years. Over her career she has developed advanced biologic products across multiple therapeutic areas, from orthopedics to wound care, and most recently led the development of EluPro™, which was acquired by Boston Scientific for $88 million.
Elutia’s team is defined by a simple standard: excellence. Elutia hires for intellect and drive, and people stay because of the mission and the team. That commitment is reflected in the depth and stability of the organization. Women comprise 54% of the workforce and 62% of leadership roles. Half of Elutia’s team members hold advanced degrees, and one-third hold doctorates. In a company founded just 10 years ago, a median tenure of 6.3 years reflects continuity throughout the company’s evolution.
“This team executes,” said Fletcher Brehler, Senior Director, Strategic Marketing. “We debate hard, align fast, and move. This isn’t chaos dressed up as innovation. It’s disciplined professionals who know exactly what we’re building and why. That kind of clarity is rare, and it makes even the hardest challenges fun.” Fletcher has been with Elutia for seven years and has been a driving force behind the product launch and success of the SimpliDerm business unit.
“Elutia is special because of the CRU,” said Michelle Williams, PhD, Chief Scientific Officer. “We hold ourselves to uncompromising standards because our patients depend on it. Our mission to humanize medicine so patients can thrive without compromise requires developing first-in-class products and disciplined regulatory execution. It’s hard, but for those who want their efforts to truly matter, Elutia is more than a great place to work. For me, it’s the only place.” Dr. Williams is a co-founder and corporate officer of Elutia and has, over her career, invented and brought products to market that have generated more than $1.5 billion in sales.
Great Place To Work® is the global authority on workplace culture, employee experience, and leadership behaviors proven to drive market-leading revenue, employee retention, and increased innovation. This data-driven certification identifies high-trust cultures that typically achieve 50% lower turnover and significantly outperform industry benchmarks for performance.
We're hiring!
Want to join a mission-driven CRU of A-players working relentlessly to improve outcomes for women with breast cancer? Explore Careers - Elutia.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
About Great Place to Work Certification™
Great Place To Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.
About Great Place To Work®
As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.
Investors:
Elutia Investor Relations
[email protected]
FAQ**
How does Elutia Inc. (Nasdaq: ELUT) plan to leverage its recent Great Place to Work certification to attract top talent in the highly competitive biotech industry?
Given that Elutia Inc. (Nasdaq: ELUT) has a median tenure of 6.3 years, what strategies are in place to maintain employee engagement and retain this talent as the company continues to grow?
With recent acquisitions like EluPro™, how does Elutia Inc. (Nasdaq: ELUT) intend to utilize its certified high-trust workplace culture to drive innovation in drug-eluting biomatrix technologies?
Considering Elutia Inc. (Nasdaq: ELUT) focuses on "humanizing medicine," what specific initiatives are being implemented to align employee goals with the company's mission to improve outcomes for patients, particularly in breast cancer treatments?
**MWN-AI FAQ is based on asking OpenAI questions about Elutia Inc. (NASDAQ: ELUT).
NASDAQ: ELUT
ELUT Trading
6.17% G/L:
$1.205 Last:
69,106 Volume:
$1.15 Open:
